Polypid Ltd (PYPD)

Feb 12, 2025, 10:44 AM EST - 10 days ago

PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 7:00 AM EST - 11 days ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Jan 30, 2025, 7:00 AM EST - 24 days ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 29, 2025, 7:00 AM EST - 25 days ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Dec 26, 2024, 10:31 AM EST - 2 months ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA AVXL

Dec 23, 2024, 7:22 PM EST - 2 months ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 11, 2024, 7:00 AM EST - 2 months ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Nov 29, 2024, 1:05 PM EST - 3 months ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 13, 2024, 2:06 PM EST - 3 months ago

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 3 months ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Oct 30, 2024, 8:00 AM EDT - 4 months ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 21, 2024, 7:00 AM EDT - 4 months ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 1, 2024, 7:00 AM EDT - 5 months ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Sep 3, 2024, 7:00 AM EDT - 6 months ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

Aug 14, 2024, 1:25 PM EDT - 6 months ago

PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 8:31 PM EDT - 7 months ago

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

Jul 31, 2024, 7:00 AM EDT - 7 months ago

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

Jun 10, 2024, 7:00 AM EDT - 9 months ago

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

May 9, 2024, 10:38 PM EDT - 10 months ago

PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 10 months ago

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 1, 2024, 7:00 AM EDT - 10 months ago

PolyPid to Participate in Citizens JMP Life Sciences Conference

Apr 30, 2024, 7:00 AM EDT - 10 months ago

PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Apr 24, 2024, 7:00 AM EDT - 10 months ago

PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

Feb 28, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

Feb 14, 2024, 11:13 AM EST - 1 year ago

PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript

Feb 14, 2024, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 12, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

Jan 31, 2024, 7:00 AM EST - 1 year ago

PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

Jan 4, 2024, 4:32 PM EST - 1 year ago

PolyPid Announces Private Placement for $16 Million in Gross Proceeds

Nov 12, 2023, 1:08 AM EST - 1 year ago

PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 7, 2023, 7:00 AM EST - 1 year ago

PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

Nov 1, 2023, 7:00 AM EDT - 1 year ago

PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023

Oct 11, 2023, 7:00 AM EDT - 1 year ago

PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Oct 9, 2023, 7:00 AM EDT - 1 year ago

PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023

Oct 4, 2023, 7:00 AM EDT - 1 year ago

PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform

Sep 22, 2023, 7:00 AM EDT - 1 year ago

PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 21, 2023, 7:34 AM EDT - 1 year ago

PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health

Sep 20, 2023, 9:15 AM EDT - 1 year ago

PolyPid Announces Reverse Share Split

Sep 19, 2023, 7:00 AM EDT - 1 year ago

PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀

Aug 9, 2023, 12:55 PM EDT - 1 year ago

PolyPid Ltd (PYPD) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 7:00 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Jul 26, 2023, 7:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023

Jun 29, 2023, 8:00 AM EDT - 1 year ago

PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections

Jun 22, 2023, 7:00 AM EDT - 1 year ago

PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

Jun 5, 2023, 4:02 PM EDT - 1 year ago

PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market

May 22, 2023, 9:00 AM EDT - 1 year ago

PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

May 10, 2023, 12:50 PM EDT - 1 year ago

PolyPid Ltd. (PYPD) Q1 2023 Earnings Call Transcript

May 10, 2023, 7:00 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results

Apr 26, 2023, 7:00 AM EDT - 1 year ago

PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023